Kopran logo

Kopran

KOPRAN NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹1,097 Cr
Volatility
Moderate
P/E Ratio
45.42
EBITDA
₹62.30 Cr
Return on Equity
4.85%
Debt to Equity
0.29
Book Value
₹109.82
52W High
₹253.71
52W Low
₹107

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 40.8%

Weaknesses

3
  • The company has delivered a poor sales growth of 6.74% over past five years.
  • Company has a low return on equity of 7.71% over last 3 years.
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
7.61% higher than 3Y
Net Income Growth
-33.42% lower than 3Y
Cash Flow Change
59.16% higher than 3Y
ROE
-34.81% lower than 3Y
ROCE
-27.81% higher than 3Y
EBITDA Margin (Avg.)
-24.65% higher than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
117
153
159
186
139
152
166
172
135
118
194
234
154
Expenses
111
130
135
164
121
137
146
155
121
123
177
201
138
Operating Profit
6.31
22.83
23.58
21.69
18.16
14.73
19.85
17.09
14.13
-5.28
17.76
32.94
15.81
OPM %
5.39%
14.96%
14.84%
11.66%
13.02%
9.72%
11.94%
9.92%
10.45%
-4.48%
9.14%
14.08%
10.27%
Other Income
2.39
0.13
2.43
9.67
2.63
1
0.17
3.26
2.56
0.03
0.07
0.09
2.05
Interest
1.83
1.94
2.24
2.59
2.18
2.23
2.16
2.77
2.54
2.09
2.67
3.17
3.28
Depreciation
3.26
2.77
3.27
3.59
3.87
3.85
4
3.87
4.26
4.28
4.42
4.52
5.77
PBT
3.61
18.25
20.5
25.18
14.74
9.65
13.86
13.71
9.89
-11.62
10.74
25.34
8.81
Tax %
22.99%
24.55%
23.02%
26.01%
24.69%
23.42%
24.96%
29.39%
24.67%
-14.63%
13.04%
25.57%
23.84%
Net Profit
2.77
13.77
15.79
18.62
11.1
7.38
10.4
9.68
7.45
-9.92
9.34
18.87
6.7
EPS in Rs
0.57
2.86
3.28
3.86
2.3
1.53
2.16
2.01
1.54
-2.06
1.94
3.91
1.39
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
326
296
310
313
358
360
492
478
551
615
630
681
700
Expenses
294
266
274
283
312
313
410
390
499
540
557
619
639
Operating Profit
31
30
36
31
46
47
82
87
52
74
73
62
61
OPM %
10%
10%
12%
10%
13%
13%
17%
18%
9%
12%
12%
9%
9%
Other Income
-48
1
11
9
3
0
18
11
3
15
4
0
2
Interest
13
13
14
9
9
9
6
5
6
9
9
10
11
Depreciation
10
8
8
9
9
10
10
11
13
13
16
17
19
PBT
-39
11
25
23
32
28
83
82
36
68
52
34
33
Tax %
0%
0%
20%
10%
24%
26%
26%
25%
24%
25%
26%
25%
—
Net Profit
-39
11
20
20
24
21
62
61
27
51
39
26
25
EPS in Rs
-9.52
2.48
4.6
4.74
5.55
4.86
14.24
12.66
5.65
10.57
7.99
5.33
5.18
Div. Payout %
0%
0%
0%
0%
0%
0%
21%
24%
53%
28%
38%
56%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
41
43
43
43
43
43
43
48
48
48
48
48
Reserves
49
57
81
101
125
146
202
378
391
443
470
482
Borrowings
86
80
95
89
97
88
66
75
75
99
148
153
Other Liabilities
99
84
78
82
85
92
128
110
135
153
178
225
Total Liabilities
275
264
298
315
351
370
439
611
650
743
844
908
Fixed Assets
102
101
104
104
113
111
112
151
165
182
208
346
CWIP
1
3
6
10
24
30
43
36
70
97
113
25
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
172
160
187
201
214
229
284
425
415
465
522
537
Total Assets
275
264
298
315
351
370
439
611
650
743
844
908
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
46
29
16
26
25
31
60
-33
34
43
42
67
Investing
-10
-9
-18
-11
-25
-13
-25
-84
-13
-44
-56
-65
Financing
-37
-19
2
-15
-1
-18
-35
123
-20
1
26
-21
Net Cash Flow
0
0
0
0
0
0
0
5
2
1
11
-19
Free Cash Flow
35
18
0
14
-6
17
43
-76
-27
-13
-17
0
CFO/OP
147
95
47
94
63
82
93
-17
90
77
76
117
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
91
70
86
75
88
94
89
97
108
126
125
141
Inventory Days
78
119
122
138
129
154
121
202
133
126
153
137
Days Payable
119
115
95
118
90
95
104
84
89
103
108
131
Cash Conversion Cycle
50
74
113
96
127
153
106
215
152
149
170
146
Working Capital Days
9
34
43
60
70
79
81
158
139
131
113
91
ROCE %
14%
14%
19%
14%
16%
14%
30%
21%
8%
14%
10%
7%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Kopran insights

68 extracted metrics + investor summaries across FY12–FY26.

Log in — free

Shareholding Pattern

FIIs0.51%Promot.44.42%Others10.92%Public44.14%As ofJun 2026

Documents

1
Concall - May 2026 May 2026
2
Concall - May 2026 May 2026
3
Concall - Nov 2025 Nov 2025
4
Concall - Nov 2025 Nov 2025
5
Concall - Jul 2025 Jul 2025

Frequently Asked Questions about Kopran

What does Kopran Ltd do?
Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.
Where is Kopran Ltd (KOPRAN) listed?
Kopran Ltd trades as KOPRAN on the NSE and under code 524280 on the BSE.
Which sector does Kopran Ltd belong to?
Kopran Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Kopran Ltd?
Kopran Ltd has a market capitalisation of ₹1,097 Cr, which places it in the Small Cap band.
What is the PE ratio of Kopran Ltd?
Kopran Ltd trades at a PE ratio of 45.42, against a book value of ₹109.82 per share.
What is the 52-week high and low of Kopran Ltd?
Over the last 52 weeks Kopran Ltd has traded between ₹107 and ₹253.71.
Does Kopran Ltd pay dividends?
Kopran Ltd has a dividend yield of 1.27%.
What is the Return on Equity (ROE) of Kopran Ltd?
Kopran Ltd reported a return on equity of 4.85%. Its debt-to-equity ratio is 0.29.

Company Information

Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.

Website kopran.com
CEO Mr. Surendra Shrikrishna Somani B.Com.
Employees 1,024
Listed 1999-06-09
Face Value ₹ 10
Issued Size 4,82,87,601

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/KOPRAN.md for Kopran Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List